Toxicity associated with tuberculosis chemotherapy in the REMoxTB study.
Conor D Tweed, Angela M Crook, Evans I Amukoye, Rodney Dawson, Andreas H Diacon, Madeline Hanekom, Timothy D McHugh, Carl M Mendel, Sarah K Meredith, Michael E Murphy, Saraswathi E Murthy, Andrew J Nunn, Patrick PJ Phillips, Kasha P Singh, Melvin Spigelman, Genevieve H Wills, Stephen H Gillespie
BMC Infect Dis | Published : 2018
BACKGROUND: The incidence and severity of tuberculosis chemotherapy toxicity is poorly characterised. We used data available from patients in the REMoxTB trial to provide an assessment of the risks associated with the standard regimen and two experimental regimens containing moxifloxacin. METHODS: All grade 3 & 4 adverse events (AEs) and their relationship to treatment for patients who had taken at least one dose of therapy in the REMoxTB clinical trial were recorded. Univariable logistic regression was used to test the relationship of baseline characteristics to the incidence of grade 3 & 4 AEs and significant characteristics (p < 0.10) were incorporated into a multivariable model. The timi..View full abstract
Awarded by Medical Research Council
Awarded by Bill & Melinda Gates Foundation